SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Defense Play in Motion - WTC Reaction
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GARY P GROBBEL who wrote (61)9/20/2001 3:34:48 PM
From: GARY P GROBBEL  Read Replies (1) of 225
 
I would add GNLB Naz 2.00 (as high today as 2.70) to the biodefense group...there are not many:

In the war against bacterial resistance to antibiotics, Genelabs Technologies targets disease at the source, developing small-molecule drugs that bind to DNA and change the activity of disease-causing genes. Its MERLIN technology identifies molecules' DNA-binding preferences and, ultimately, which sequences will host DNA-binding drugs. Applications include cancer therapies and treatments for bacterial and viral infections. The company is awaiting FDA approval for Aslera, a new therapy for lupus. Genelabs also researches genetic technologies for use against biological warfare agents. Subsidiary Genelabs Diagnostics makes diagnostic test kits, reagents, and equipment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News